• Net Contracted Licences increased 9% to 110,000
• Contracted Annual Recurring Revenue (ARR) up 10% to A$5.4 million
• Net Licence Retention rate at 106%, highlighting customer expansion

PainChek Ltd (ASX: PCK), the developer of the world's first smart device-based pain assessment and monitoring application, has reported strong quarterly sales growth for the period ended 30 June 2025. The key highlights include a 9% increase in Net Contracted Licences to 110,000, a 10% rise in Contracted Annual Recurring Revenue (ARR) to A$5.4 million, and a Net Licence Retention rate of 106%, indicating successful customer expansion. The company secured new clients across the UK, Australia, and Canada, with a mix of 1 and 2-year agreements. The new agreements feature fixed implementation and billing, demonstrating the scalable nature of PainChek's platform. The achievement of over 12 million global pain assessments highlights the strong and growing clinical utility of PainChek's technology, which has also received positive outcomes from a Scottish Inspectorate validation study. This endorsement positions PainChek strategically within the Scottish Government's aged care strategy review, with a comprehensive cost-benefit analysis indicating strong potential for further adoption and integration into national healthcare frameworks.

With a strong sales pipeline in existing markets and new products and geographies expected to come online in the near term, the Company is well set up for substantial growth looking ahead.